推进抗高血压药物的开发
Fay Pu1, Yanrong Liu2, Fozia Zahir Ahmed3
1Intensive care units, University Hospitals of Morecambe Bay NHS Foundation Trust, Kendal, UK.
British journal of pharmacology
|June 3, 2025
概括
创新的高血压治疗方法,如阿尔多氨酸合成酶抑制剂和基于RNA的疗法,可以改善血压控制和心脏和脏的益处. 这些新的策略针对潜在的机制来克服耐药性并提高患者的治疗结果.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 高血压影响全球超过10亿人,导致严重的心血管问题.
- 目前的治疗方法面临着诸如耐药性,副作用和不良坚持等挑战,阻碍了最佳的血压控制.
研究的目的:
- 审查用于管理高血压的创新治疗策略.
- 探索解决治疗耐药性,不良影响和坚持挑战的新方法.
主要方法:
- 对新出现的药理学药物的综述,包括阿尔多氨酸合成酶抑制剂,矿物质皮质类受体对抗剂和内甲素受体对抗剂.
- 分析新的治疗方式,如基于RNA的疗法 (例如,zilebesiran),AT2受体激动剂,ACE2激活剂和NAD+增强化合物.
- 讨论支持策略,如肠道微生物组调节和固定剂量组合药丸.
主要成果:
- 阿尔多氨酸合成酶抑制剂和非类固醇矿物质皮质类受体对抗剂表明改善了血压控制,增强了心脏和脏的保护,降低了高血症的风险.
- 内甲素受体对抗剂通过向血管收缩,显示出治疗耐药高血压的潜力.
- 基于RNA的疗法,如zilebesiran,通过通过低频剂量抑制血管素原来持续降低血压.
结论:
- 新兴疗法针对特定的病理生理路径,以精确的方法来管理高血压.
- 新的策略有望改善血压控制,减少全球高血压负担,并改善患者的治疗结果.
- 未来的研究和这些创新的临床应用对于推进高血压护理至关重要.
相关概念视频
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
56
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
56
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
01:23Antihypertensive Drugs: Vasodilators
660
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
660
01:28Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
849
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
849
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
642
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
642